GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mangoceuticals MGRX · USD

Consumer Staples · US listing · 🇺🇸 United States

Compare

0.20

+1.08%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Mangoceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

Mangoceuticals is based in Dallas, Texas and is incorporated in Texas. Its shares trade on Nasdaq under the ticker MGRX. The SEC classifies its business as misc health & allied services, nec. In the fiscal year to 31 December 2025, it reported revenue of $456,021 and a net loss of $20.6m. At that date it held total assets of $16.1m and shareholders' equity of $15.2m.

Read the filing on SEC.gov ↗

Company facts

Sector
Consumer Staples
Industry
Consumer Staples Distribution & Retail
Listed since
21 Mar 2023
Website
mangorx.com ↗
Head office
15110 DALLAS PKWY, SUITE 600, DALLAS, TX, 75248
Incorporated in
TX
Classification
Services-Misc Health & Allied Services, NEC
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Jacob CohenChairman of the Board, Chief Executive Officer, since 2021$630,000
  • Mr. Eugene JohnstonChief Financial Officer$117,750
  • Mrs. Amanda HammerChief Operating Officer$185,000
  • Ms. Lorraine DalessioIndependent Non-Executive Director$35,000
  • Mr. Alex HamiltonIndependent Non-Executive Director$35,000
  • Dr. Kenny MyersIndependent Non-Executive Director$35,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Mangoceuticals Inc. offers a telemedicine platform for men's wellness with unique ED products like Mango ED.
  • The company's Mango ED product features Tadalafil, Oxytocin, and L-Arginine in specific dosages.
  • Mangoceuticals has a telehealth platform connecting consumers to licensed healthcare professionals via MangoRX.com.

Weaknesses

  • The company's IPO on March 21, 2023, is recent, limiting market experience.
  • Mangoceuticals focuses solely on men's wellness, restricting product diversity.
  • The firm's commercial launch of Mango ED is still in preparation phase.

Opportunities

  • The growing telehealth market in the US presents expansion potential for Mangoceuticals.
  • Mango ED product can target the large men's health segment in the US market.
  • Mangoceuticals can leverage its telemedicine platform for additional wellness services.

Threats

  • Mango ED product faces regulatory scrutiny in the US healthcare sector.
  • The telemedicine industry faces increasing competition from established healthcare providers.
  • Mangoceuticals' reliance on a single product line poses market vulnerability.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.